Compare OSUR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSUR | CRDF |
|---|---|---|
| Founded | 2000 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.2M | 142.1M |
| IPO Year | 1986 | N/A |
| Metric | OSUR | CRDF |
|---|---|---|
| Price | $2.40 | $2.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $3.00 | ★ $10.63 |
| AVG Volume (30 Days) | 742.3K | ★ 914.5K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $125,703,000.00 | $501,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.08 | $1.90 |
| 52 Week High | $4.22 | $5.00 |
| Indicator | OSUR | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 43.86 | 65.93 |
| Support Level | $2.41 | $2.32 |
| Resistance Level | $2.53 | $2.59 |
| Average True Range (ATR) | 0.11 | 0.13 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 15.52 | 94.69 |
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.